MedX Health reviews 2025

Executive Summary

• MedX Health Corp. released its 2025 Year-in-Review, highlighting over $2 million in investments toward technology platform development, intellectual property, and operational infrastructure to prepare for a large-scale commercial rollout in 2026.
• The company appointed new executive leadership in Q3 2025, including a CEO, CTO, and COO, to consolidate technology development and strengthen commercial readiness.
• Key operational milestones include the expansion of the DermSecure image database to ~85,000 clinically reviewed images, the launch of new photobiomodulation product lines (LumaVet and Oralase), and the release from an exclusive licensing agreement with Procter & Gamble, allowing direct commercial pursuit in beauty and aesthetics markets.

Key Details

• Financial Investment: Over $2 million invested in fiscal 2025 in technology platform, IP portfolio, compliance, and operational infrastructure.
• Executive Appointments:
  • Q3 2025: Appointed new Chief Executive Officer.
  • Q3 2025: Appointed first Chief Technology Officer (CTO), consolidating responsibility for technology development across specialist teams.
  • Q3 2025: Appointed Chief Operating Officer (COO).
• DermSecure Platform & SIAscopy:
  • Proprietary image database expanded to approximately 85,000 clinically reviewed skin images.
  • Data includes detailed information on blood, melanin, and collagen to support AI-driven skin analysis and clinical decision-making.
  • SIAscopy IP remains the industry standard for longitudinal chromophore measurement and non-invasive skin analysis.
• Commercial Agreements & Partnerships:
  • Health Partners Group: Executed commercial agreement in Q1 2025; phased commercial rollout to employer groups is proceeding as planned, expected to commence in Q1 2026.
  • Procter & Gamble (P&G): Released from prior exclusive licensing arrangement in Q1 2025, enabling MedX to directly pursue licensing and commercial opportunities in skin health, aesthetics, and beauty markets.
  • CRO Services: Provided technology and services to more than 26 Contract Research Organizations (CROs) across multiple jurisdictions in 2025.
• Photobiomodulation (Cold Laser) Division:
  • Generated revenues during 2025, reflecting product line expansion and channel development.
  • Products hold FDA clearance and international regulatory approvals; operates within ISO 13485-certified quality system.
  • New Product Launches:
    • LumaVet: Veterinary-focused cold-laser system for pain management and tissue healing.
    • Oralase: Dental laser SKU targeting oral care and dental practice use; expected to be a meaningful growth contributor in 2026.
• Strategic Outlook: Company views 2025 as a year of platform development and operational readiness, positioning for expanded commercial activities in 2026 subject to market conditions and regulatory considerations.

Notable Quotes

• No direct quotes from the CEO or President were included in the provided text.